公司资料
Absci Corporation 股价、新闻与催化剂
- 股票代码:
- ABSI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
9.55 USD (+2.91%)
收盘价
最后更新: 2026年8月21日
990M USD
市值
股价为何变动
As of Aug 21, 2026, ABSI closed up 2.91% at $9.55. No new same-company headline was identified in the current news window.
公司概览
AI-Enabled Biologic Design
Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models.
ABS-201
ABS-201 is a long-acting antibody against the prolactin receptor. Its pharmacokinetic profile is intended to support only a few injections over a six-month treatment period.
Pattern Hair Loss
The Phase 1/2a HEADLINE study evaluates ABS-201 as a potentially durable treatment for male and female pattern hair loss through a mechanism distinct from existing therapies.
Endometriosis
Absci is also advancing ABS-201 as a potential non-sex-steroid, disease-modifying treatment that could address both pain and lesion growth in endometriosis.
Prolactin-Focused Pipeline
ABS-202 is a second anti-prolactin-receptor antibody in preclinical development for an undisclosed inflammatory and immunologic indication, extending the company's internal prolactin biology franchise.
未来催化剂
- Interim proof-of-concept data from the HEADLINE study of ABS-201 in pattern hair loss in the second half of 2026.
- Initiation of a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
- Full proof-of-concept data from HEADLINE in early 2027.
- Potential proof-of-concept data from the Phase 2 endometriosis study in the second half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。